BECTON DICKINSON & CO Q4 FY2026 earnings call

• Strategic Transformation: Completed the separation of the life sciences business, establishing a focused med-tech portfolio. Entered into a landmark partnership with the U.S. government committing $19 billion in domestic investment over several years, including $3 billion for manufacturing expansion, providing tariff relief under Section 232.
• Commercial Execution ('Compete'): Raised the bar on commercial execution via AI sales tools, talent investments, and performance-based compensation. Key platforms like Advanced Patient Monitoring (APM) and Alaris achieved significant market share gains and margin expansion. Pharmacy automation won all six central fill opportunities in Q4 with VMAX attached.
• Innovation Pipeline ('Innovate'): Compressed product launch times by an average of 10 months through R&D realignment. Received FDA approval for Liberty Tip StentGraft and 510K clearance for Phasix ST peristomal mesh. Deployed 'Encata' AI platform with a 95% attachment rate in pharmacy automation.
• Operational Excellence ('Deliver'): Achieved approximately 8% gross productivity in plants with customer service levels above 90% via over 2,000 Kaizen events. Completed a $200 million cost-out program. Free cash flow increased 42% to $2.9 billion, with conversion rising from 57% to 74%.
• AI Integration: Deploying 'Cognite' AI platform across manufacturing for demand and production planning. Utilizing AI in sales for hiring, planning, and performance analysis. Created an AI Center of Excellence in Irvine, California.

Medical Essentials reported $5.3 billion in revenue growth of 5.9%. Within this segment, Medical Device Solutions (MDS) saw solid mid-single-digit growth driven by share gains in vascular access management. Specimen Management grew high single digits due to share gains in BD vacuum containers and strong infusion set performance. Biopharma Systems grew 7%, led by double-digit growth in biologics (specifically GLP-1 therapies), partially offset by moderating vaccine headwinds. Interventional grew 7.6%, with high single-digit growth in Peripheral Intervention and Urology & Critical Care (UCC), and solid mid-single-digit growth in Surgery, driven by Advanced Tissue Regeneration.

• Fiscal 2027 Revenue: Expects low single-digit growth for the full year. Currency is estimated to be a headwind of ~70 basis points. Excluding the ~200 basis point impact from the Alaris capital comparison, guidance reflects mid-single-digit growth at the midpoint.
• Margins: Adjusted operating margins are expected to be roughly flat year-over-year. This assumes an inflationary environment, mitigated by BD Excellence initiatives and favorable mix.
• Earnings Per Share (EPS): Adjusted EPS is guided between $13.10 and $13.30. Weighted average shares outstanding are expected to be ~273 million.
• Tax Rate: Expected adjusted tax rate is between 16% and 17%.
• Phasing: Q1 revenue growth is expected at the low end of the range due to seasonality and specific one-time dynamics (Alaris pressure and APM system integration). Earnings growth is expected to accelerate in Q2 and the second half of the year. Q1 adjusted EPS is guided between $2.32 and $2.37.

• Tariff Uncertainty: While a partnership provides potential relief from Section 232 tariffs, the final scope and implementation timing remain unconfirmed. Current guidance does not include benefits from this deal; any upside would occur if tariffs are implemented as agreed.
• System Integration Risks: The transition to new IT systems in Advanced Patient Monitoring (APM) requires prudent forecasting. Management adopted a conservative approach for Q1 to account for potential integration hiccups, though early signs indicate smooth operations.
• Inflationary Pressures: The company anticipates an inflationary environment in FY27, which may impact costs, though BD Excellence and pricing actions are designed to offset these headwinds.
• Biologics/Vaccine Volatility: Vaccine volumes declined 11% in Q4, though management expects this headwind to dissipate in FY27. Long-term biologics growth depends on successful capture of autoinjector value as biosimilars enter the market.

Q: Analyst asked about the interplay between top-line investment and margin structure, specifically how commercial investments in areas like PI and APM affect margins long-term. / A: Management confirmed that targeted investments in growth levers drive accretive gross margins because these high-growth platforms expand their share of total revenue, creating a flywheel effect on margins. They emphasized that while tariffs were absorbed in FY26, future margin expansion will come from the mix shift toward these higher-margin growth drivers, supported by BD Excellence operational efficiencies and disciplined G&A cost actions. CFO noted that continued investments in sales and R&D are essential to maintain this trajectory.

Q: Analyst questioned the rationale for guiding Q1 revenue to the low end of the full-year range despite strong momentum, asking if it was conservatism or functional issues. / A: Management explained two primary factors: the Alaris comparison creates a more acute ~250 basis point headwind in Q1 compared to the rest of the year, and the recent go-live of new IT systems in APM required a conservative forecast to buffer against integration risks. CEO clarified that there is no drop-off in demand or orders; rather, they prudently shifted some shipment volume expectations to Q2 to ensure accuracy. He noted that since the system went live successfully, there is a possibility of rebalancing earnings positively back to Q1 if execution remains smooth.

Q: Analyst asked for clarity on global healthcare policy trends, specifically regarding U.S. political shifts, European consolidation, and pricing pressures in China. / A: CEO stated that U.S. utilization remains strong, evidenced by increased blood tube collection per patient, and capital spending is selective but robust in areas like pharmacy automation. Regarding politics, BD works with any administration, focusing on value and access, and views the government partnership as a stable anchor. In Europe, strong performance is driven by labor-saving pharmacy automation solutions amid hospital consolidation. On China, management noted it is a smaller portion of the business now and represents a continuation of base dynamics rather than an incremental headwind, as they have managed local competitive pressures for years.

Q: Analyst inquired about the durability of the biologic/GLP-1 franchise given competitor caution, asking if growth is driven by share gains or product mix. / A: CEO highlighted BD’s exceptionally high win rate for new molecules and biosimilars in the biologics space, attributing success to unique technologies like XSI coatings and Neopak products. He explained that as biosimilars emerge, BD captures significantly higher ASPs by selling autoinjectors alongside syringes, citing Brazil as an early example. He also noted that the vaccine headwind seen in Q4 has moderated significantly and is expected to disappear entirely in FY27, leaving only the Alaris comparison as a near-term drag.

Q: Analyst asked about the components of flat operating margin guidance for FY27 and BD's strategic view on AI applications. / A: CFO clarified that flat margins reflect the balance between strategic commercial/R&D investments and inflationary pressures, which are being offset by BD Excellence supply chain gains and pricing power. Excluding the Alaris headwind, margins would actually expand. CEO detailed AI strategy, highlighting the 'Encata' platform embedding AI into pharmacy devices for data analytics, and the 'Cognite' platform automating manufacturing planning. He also noted AI use in sales force optimization and created a dedicated AI Center of Excellence to leverage technology for both clinical outcomes and internal efficiency.